STAT News

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

By STAT News

1 min read
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights